Who is sponsoring NCT04584619?

NCT04584619 is sponsored by Clariance.

What drugs are being tested in NCT04584619?

Interventions in NCT04584619: Spine fusion surgery with Clariance Idys TLIF 3DTi.

What condition does NCT04584619 study?

NCT04584619 studies Degenerative Disc Disease, Grade 1 Spondylolisthesis.

Is NCT04584619 still recruiting?

NCT04584619 is currently status unknown. Last updated 29 November 2021.

Last reviewed 2021-11-29 · How we verify

NCT04584619

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Idys™ TLIF 3DTi Post Market Clinical Follow-up

Status unknown Last updated 29 November 2021

What this trial tests

trial testing Spine fusion surgery with Clariance Idys TLIF 3DTi in Degenerative Disc Disease in 25 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
30 September 2023

31 December 2023

Quick facts

Lead sponsor	Clariance
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	25
Start date	1 October 2020
Primary completion	30 September 2023
Estimated completion	31 December 2023
Sites	1 location across United States

Drugs / interventions tested

Spine fusion surgery with Clariance Idys TLIF 3DTi

Conditions studied

Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
Grade 1 Spondylolisthesis — all drugs for Grade 1 Spondylolisthesis →

Sponsor

Clariance — full company profile →

Who can join

18 and older, any sex, with Degenerative Disc Disease or Grade 1 Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this observational post-marketing study is to provide additional information on the safety and effectiveness of Idys™ TLIF 3DTi at up to 24 months post transforaminal lumbar fusion in usual surgical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Degenerative Disc Disease

Currently open trials in the same condition.

NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04584619 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clariance
Last refreshed: 29 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04584619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing